Kite Pharma, Inc.

Saikat Banerjee

Ruth E Winter

Christopher Ecker

Yoonjung Shin

The present disclosure relates to the field of cell therapy, and more specifically, to improving CAR and/or TCR function through improvement of cytokine signaling. Disclosed are embodiments of a membrane bound interleukin 15 (IL-15)-IL-15Ralpha sushi domain chimeric receptor. The chimeric receptor may comprise a FAS transmembrane domain or an IL-7 transmembrane domain. Different embodiments of the chimeric receptor have different polypeptide lengths between the IL-15 region and the transmembrane domain.

Immune cell function

Immune cell engineered to inhibit the endogenous expression of one or more of Blimp-1 and A20 and/or overexpress one or more of exogenous TCF7 and Bach2. Method of treating cancer, comprising administering the cells described herein. Method of increasing one or more of a peak fold proliferation rate, a killing efficiency, or inducing the cellular characteristics associated with naïve phenotype of an immune cell, comprising introducing an exogenous construct encoding a CAR or a TCR, and inhibiting the endogenous expression of one or more of Blimp-1 and A20, and/or introducing an exogenous construct encoding one or more of TCF7 and Bach2. Method of generating a modified immune cell, comprising introducing an exogenous construct encoding a CAR or a TCR, and inhibiting the endogenous expression of one or more of Blimp-1 and A20, and/or introducing an exogenous construct encoding one or more of TCF7 and Bach2.

Growing community of inventors

Oakland, CA, United States of America

Saikat Banerjee